BioSpace News Archive

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide a business update at the upcoming Solebury Trout Virtual Investor Conference on Tuesday, March 31, 2020 at 12:30pm EDT. A webcast of the presentation will be available in the investors section of the Company’s websit

ENHERTU ® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer Approval based on the pivotal DESTINY-Breast01 trial represents third approval ever under the conditional early approval system in Japan, and follows recent U.S. accelerated approval of ENHERTU ® ENHERTU ® represents the second innovative treatment from the oncology pipeline of Daiichi Sankyo to be approved for use in Japan in past

Name Change Emphasizes Company Vision and Mission to Combat Cancer -

Moderna, Inc., (Nasdaq: MRNA) today announced that Stéphane Bancel, Chief Executive Officer will participate in the MIT Laboratory for Financial Engineering (LFE) and Golub Center for Finance and Policy (GCFP) Distinguished Lecture Series, “Dealing with Coronavirus: An Industry Perspective” on Wednesday, April 1 from 4:30-6:00 p.m. EDT.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today released the following letter from its CEO John Dobak, M.D.: We at DermTech are monitoring the COVID-19 pandemic daily. In these uncertain times, the health and safety of our employees and other stakeholders is a top priority. In an effort to limit the spread of COVID-19, we are man

A study evaluating endoscopic procedure time removing complex colorectal polyps shows superiority of DiLumen over control group. WESTPORT, Conn.--( BUSINESS WIRE )-- Connecticut-based medical device innovator Lumendi, LLC ( www.lumendi.com ) reports that its 1:1 randomized trial of the DiLumen Endolumenal Interventional Platform (EIP) successfully met the primary endpoint of an IRB-approved 200-patient prospective study. The study evaluates DiLumen’

Financing co-led by Cobro Ventures and Taiwania Capital Management Corporation; Michael Huang, Managing Partner at Taiwania joins the Regenacy Board of Directors- WALTHAM, Mass.--( BUSINESS WIRE )-- Regenacy Pharmaceuticals , a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced the closing of a $30 million Series A financing. The financing was co-led by Cobro

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its synthetic SARS-CoV-2 RNA Controls to provide quality control for the development, verification, and ongoing validation for diagnostic tests are now included on the U.S. Food and Drug Administration (FDA) website as refer

Astrotech Corporation [NASDAQ: ASTC] today announced that the BreathTest-1000™ is under development to screen for volatile organic compound (VOC) metabolites found in a person’s breath that could indicate they may have an infection, including Coronavirus Disease 2019 (“COVID-19”) or the resulting disease, pneumonia. The Company believes that its unique mass spectrometry technology that was initially developed in collabora

Masimo (NASDAQ: MASI) today announced the results of a recently published ten-year retrospective study in which researchers at Dartmouth-Hitchcock Medical Center investigated the impact of an integrated clinical surveillance monitoring system, using Masimo SET® and Patient SafetyNet™ technologies, on mortality related to use of prescribed opioids in the general ward.